BUZZ - Inovio Pharma shares soar after US Food and Drug Administration approves rare disease therapy

October 30 - ** Inovio Pharmaceuticals (INO.O) shares surged 293.4% in after-hours trading to $2.36

** The U.S. Food and Drug Administration (FDA) approved (link) the company’s therapy for treating a rare respiratory disease, marketed under the brand name Voceryq

** Inovio’s therapy is approved for treating patients with recurrent respiratory papillomatosis, a condition that causes growths within the airways and typically requires repeated surgeries

** Inovio plans to commercialize the therapy independently in the U.S. and is working with Syneos Health to support its market launch

** As of the close of the previous trading day, the stock was down 65.4% year-to-date

(To facilitate non-native English speakers, Reuters automatically translates its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for readers’ convenience. Reuters accepts no responsibility for any harm or loss caused by use of the automated translation function.)